Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Giovanni Pellicanò
Lipid Profile Improvement in Virologically Suppressed HIV-1-infected Patients Switched to Dolutegravir/Abacavir/Lamivudine: Data From the SCOLTA Project
Infection and Drug Resistance
Infectious Diseases
Pharmacology
Related publications
Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching From Ritonavir-Boosted Protease Inhibitors to Raltegravir
AIDS Research and Human Retroviruses
Virology
Infectious Diseases
Immunology
No Difference in Effectiveness of Treatment Simplification to Boosted or Unboosted Atazanavir Plus Lamivudine in Virologically Suppressed in HIV-1-infected Patients
PLoS ONE
Multidisciplinary
Switch From Enfuvirtide to Raltegravir in Virologically Suppressed HIV-1 Infected Patients: Effects on Level of Residual Viremia and Quality of Life
Journal of Clinical Virology
Virology
Infectious Diseases
Dolutegravir/Abacavir/Lamivudine Versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study
Antiviral Therapy
Infectious Diseases
Pharmacology
Nevirapine-Raltegravir Combination, a NRTI and PI/r Sparing Regimen, as Maintenance Antiretroviral Therapy in Virologically Suppressed HIV-1-infected Patients
Antiviral Therapy
Infectious Diseases
Pharmacology
Abacavir–Lamivudine Versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy
New England Journal of Medicine
Medicine
Pharmacokinetics and Acceptability of Once- Versus Twice-Daily Lamivudine and Abacavir in HIV Type-1-Infected Ugandan Children in the ARROW Trial
Antiviral Therapy
Infectious Diseases
Pharmacology
96-Week Results of Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Plus Efavirenz, in Antiretroviral-Naive, HIV-1-infected Adults: ASSERT Study
Antiviral Therapy
Infectious Diseases
Pharmacology
Dual Therapy With Renally Adjusted Lamivudine and Dolutegravir: A Switch Strategy to Manage Comorbidity and Toxicity in Older, Suppressed Patients?
HIV Medicine
Health Policy
Infectious Diseases
Pharmacology